Voyager Therapeutics (VYGR) Change in Accured Expenses (2014 - 2026)

Voyager Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at -$5.1 million in Q1 2026.

• Quarterly Change in Accured Expenses changed 0.16% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 263.39% YoY) and the FY2025 annual result came in at -$2.5 million, up 5.73% from the prior year.
• Change in Accured Expenses slipped to -$5.1 million in Q1 2026 per VYGR's latest filing, from -$3.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.8 million in Q4 2023 and troughed at -$9.3 million in Q1 2024.
• A 5-year average of -$259941.2 and a median of $1.2 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 1065.84% in 2022, then sank 7527.05% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$4.7 million in 2022, then soared by 223.21% to $5.8 million in 2023, then sank by 52.71% to $2.7 million in 2024, then slumped by 216.71% to -$3.2 million in 2025, then plunged by 60.94% to -$5.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$5.1 million, -$3.2 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.